Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This study aims to assess the safety and tolerability of AMG 609 when administered subcutaneously as single doses in participants with non-alcoholic fatty liver disease (NAFLD).
Epistemonikos ID: 665224814d0a685db107d0c02a0fa48aa6071fff
First added on: May 08, 2024